ACTR5 controls CDKN2A and tumor progression in an INO80-independent manner.

ACTR5 controls CDKN2A and tumor progression in an INO80-independent manner.
复制标题

DOI:
10.1126/sciadv.adc8911
复制
发表时间:
2022-12-23
期刊:
影响因子:
13.6
通讯作者:
--
中科院分区:
综合性期刊1区
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

细胞周期的表观遗传失调是包括肝细胞癌(HCC)在内的多种癌症肿瘤发生的一个标志。然而,异常细胞周期信号传导和治疗反应背后的表观遗传机制仍不清楚。在这里,我们使用了一种以表观遗传学为重点的CRISPR干扰筛选,并确定了ACTR5(肌动蛋白相关蛋白5),INO80染色质重塑复合体的一个组成部分,对HCC肿瘤进展至关重要。抑制ACTR5激活CDKN2A表达,消融CDK/ e2f驱动的细胞周期信号,减弱HCC肿瘤生长。此外,高密度CRISPR基因切片扫描显示,与其他INO80复合体成员相比,ACTR5及其相互作用伙伴IES6具有明显的HCC特异性,这表明ACTR5/IES6支持HCC增殖的机制与INO80无关。最后,我们的研究揭示了ACTR5/ ies6靶向与CDK药物抑制在治疗HCC中的协同作用。这些结果表明,表观遗传调控因子、肿瘤抑制因子和细胞周期机制之间的动态相互作用可能为HCC联合治疗提供新的机会。ACTR5/IES6通过CDKN2A的表观遗传沉默促进肿瘤进展。
Epigenetic dysregulation of cell cycle is a hallmark of tumorigenesis in multiple cancers, including hepatocellular carcinoma (HCC). Nonetheless, the epigenetic mechanisms underlying the aberrant cell cycle signaling and therapeutic response remain unclear. Here, we used an epigenetics-focused CRISPR interference screen and identified ACTR5 (actin-related protein 5), a component of the INO80 chromatin remodeling complex, to be essential for HCC tumor progression. Suppression of ACTR5 activated CDKN2A expression, ablated CDK/E2F-driven cell cycle signaling, and attenuated HCC tumor growth. Furthermore, high-density CRISPR gene tiling scans revealed a distinct HCC-specific usage of ACTR5 and its interacting partner IES6 compared to the other INO80 complex members, suggesting an INO80-independent mechanism of ACTR5/IES6 in supporting the HCC proliferation. Last, our study revealed the synergism between ACTR5/IES6-targeting and pharmacological inhibition of CDK in treating HCC. These results indicate that the dynamic interplay between epigenetic regulators, tumor suppressors, and cell cycle machinery could provide novel opportunities for combinational HCC therapy. ACTR5/IES6 promotes tumor progression via epigenetic silencing of CDKN2A.
DOI: 10.1038/s41586-018-0021-6
发表时间: 2018-04
期刊: Nature
影响因子: 64.8
作者:
Ayala R;Willhoft O;Aramayo RJ;Wilkinson M;McCormack EA;Ocloo L;Wigley DB;Zhang X
通讯作者: Zhang X
DOI: 10.1038/s41586-021-03819-2
发表时间: 2021-08
期刊: Nature
影响因子: 64.8
作者:
Jumper J;Evans R;Pritzel A;Green T;Figurnov M;Ronneberger O;Tunyasuvunakool K;Bates R;Žídek A;Potapenko A;Bridgland A;Meyer C;Kohl SAA;Ballard AJ;Cowie A;Romera-Paredes B;Nikolov S;Jain R;Adler J;Back T;Petersen S;Reiman D;Clancy E;Zielinski M;Steinegger M;Pacholska M;Berghammer T;Bodenstein S;Silver D;Vinyals O;Senior AW;Kavukcuoglu K;Kohli P;Hassabis D
通讯作者: Hassabis D
DOI: 10.1111/j.1872-034x.2007.00141.x
发表时间: 2007-11-01
影响因子: 4.2
作者:
Kondo, Yutaka;Shen, Lanlan;Sekido, Yoshitaka
通讯作者: Sekido, Yoshitaka
DOI: 10.1038/nbt.3437
发表时间: 2016-02
影响因子: 46.9
作者:
Doench JG;Fusi N;Sullender M;Hegde M;Vaimberg EW;Donovan KF;Smith I;Tothova Z;Wilen C;Orchard R;Virgin HW;Listgarten J;Root DE
通讯作者: Root DE
DOI: 10.1016/j.cell.2017.05.046
发表时间: 2017-06-15
期刊: Cell
影响因子: 64.5
作者:
Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu;Cancer Genome Atlas Research Network
通讯作者: Cancer Genome Atlas Research Network